Pharma BD Deal Intelligence
AstraZeneca's $1.1B bet on Icosavax bought IVX-A12, a bivalent RSV/human metapneumovirus vaccine candidate for older adults, and closed in February 2024. Nearly two years later the Phase 2 data are in but no Phase 3 trial has been registered, leaving the pivotal step that justified the price still unproven.
AstraZeneca acquired Icosavax for $1.1B for RSV vaccine development.
AstraZeneca will pay up to $1.1B to acquire Icosavax, a University of Washington biotech spinout developing VLP vaccines
AstraZeneca completes Icosavax acquisition for $1.1bn, gaining RSV and hMPV combination vaccine candidate IVX-A12
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
AstraZeneca acquired Icosavax for up to $1.1B ($800M upfront plus a contingent value right of up to ~$5/share) to add IVX-A12, a bivalent protein virus-like-particle vaccine candidate targeting RSV and human metapneumovirus (hMPV) in older adults. The deal closed in February 2024. As of late 2025, the IVX-A12 Phase 2 program had completed (NCT05903183, NCT06481579) but no Phase 3 trial had been publicly registered, so the 'Phase III-ready' asset that underpinned the acquisition had not yet visibly advanced to pivotal development.
5M US cases/yr · $7.0B US RSV Vaccine/Prevention Market · ~14,000 Annual US RSV Deaths (Adults 65+)
Respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) cause significant respiratory illness, particularly in older adults and immunocompromised populations. AstraZeneca acquired Icosavax for its IVX-A12, a potential first-in-class combination protein VLP vaccine targeting both RSV and hMPV simultaneously, with positive Phase II data.
The RSV prevention market has exploded with Arexvy (GSK) and Abrysvo (Pfizer) approved as adult RSV vaccines in 2023, plus Beyfortus (nirsevimab, AZ/Sanofi) for infants. IVX-A12 differentiates as a combination RSV+hMPV vaccine using virus-like particle (VLP) technology. AZ already has RSV presence through Beyfortus antibody prophylaxis, making Icosavax acquisition complementary.
AstraZeneca completed $1.1B acquisition of Icosavax, gaining IVX-A12 bivalent VLP vaccine for RSV and hMPV respiratory infections.
AZ advanced bivalent VLP vaccine through development, complementing existing RSV antibody Beyfortus with vaccine approach.
Per ClinicalTrials.gov, the IVX-A12 Phase 1 (NCT05664334) and Phase 2 (NCT05903183, NCT06481579) studies are all marked COMPLETED, but no Phase 3 / pivotal trial had been registered as of late 2025 - the 'Phase III-ready' asset behind AstraZeneca's $1.1B Icosavax acquisition had not yet advanced to pivotal development ~2 years post-close.
Bivalent RSV/hMPV concept differentiated. Complements Beyfortus antibody. In clinical development with regulatory path to be established.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Icosavax Inc. (this deal) | 2023 | $1.1B | 61 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2023 deals · AstraZeneca PLC deals · Infectious Disease deals